Isolation of exophiala dermatitidis from pigmented sputum in a cystic fibrosis patient

Pediatric Pulmonology

Volumn 45, Issue 5, 2010, Pages 508-510

  Griffard, Emily A ^a   Guajardo, Jesus R ^a   Cooperstock, Michael S ^a   Scoville, Caryn L ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Colonization; Cystic fibrosis; Fungus; Pulmonary

Indexed keywords

CEFAZOLIN; COTRIMOXAZOLE; DORNASE ALFA; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; ITRACONAZOLE; LEVALBUTEROL; MICAFUNGIN; MINOCYCLINE; NAFCILLIN; TOBRAMYCIN; VORICONAZOLE;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BREATHING EXERCISE; BRONCHOSCOPE; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXOPHIALA; EXOPHIALA DERMATITIDIS; FEMALE; FUNGAL COLONIZATION; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; LUNG INFECTION; MYCOSIS; PENICILLIUM; PRIORITY JOURNAL; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTIFUNGAL AGENTS; CYSTIC FIBROSIS; EXOPHIALA; FEMALE; HUMANS; LUNG DISEASES, FUNGAL; MYCOSES; PYRIMIDINES; RECURRENCE; SPUTUM; TRIAZOLES;

EID: 77952161398     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21187     Document Type: Article

References (23)

1. Haase G, Skopnik H, Kusenbach G. Exophiala dermatitidis infection in cystic fibrosis. Lancet 1990;336:188-189. (Pubitemid 20225031)
2. ARUP National Reference Laboratory CW, Salt Lake City, UT 84108-1221 & Fungal Testing Laboratory at the University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-83900 who performed the fungal identification.
3. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681-689.
4. Horre R, Schaal KP, Siekmeier R, Sterzik B, de Hoog GS, Schnitzler N. Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study. Respiration 2004;71:360-366. (Pubitemid 39179171)
5. Haase G, Skopnik H, Groten T, Kusenbach G, Posselt HG. Long-term fungal cultures from sputum of patients with cystic fibrosis. Mycoses 1991;34:373-376.
6. Mussaffi H, Greif J, Kornreich L, Ashkenazi S, Levy Y, Schonfeld T, Blau H. Severe allergic bronchopulmonary aspergillosis in an infant with cystic fibrosis and her asthmatic father. Pediatr Pulmonol 2000;29:155-159. (Pubitemid 30060968)
7. Greenebaum E, Copeland A, Grewal R. Blackened bronchoalveolar lavage fluid in crack smokers. A preliminary study. Am J Clin Pathol 1993;100:481-487. (Pubitemid 23346193)
8. Wilson R, Sykes DA, Watson D, Rutman A, Taylor GW, Cole PJ. Measurement of Pseudomonas aeruginosa phenazine pigments in sputum and assessment of their contribution to sputum sol toxicity for respiratory epithelium. Infect Immun 1988;56:2515-2517.
9. Eide J. Pathogenesis of generalized melanosis with melanuria and melanoptysis secondary to malignant melanoma. Histopathology 1981;5:285-294. (Pubitemid 11039343)
10. Klinger JR, Bensadoun E, Corrao WM. Pulmonary complications from alveolar accumulation of carbonaceous material in a cocaine smoker. Chest 1992;101:1171-1173.
11. Tashkin DP, Gorelick D, Khalsa ME, Simmons M, Chang P. Respiratory effects of cocaine freebasing among habitual cocaine users. J Addict Dis 1992;11:59-70. (Pubitemid 23036581)
12. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46:1032-1037.
13. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006;50:917-921. (Pubitemid 43327795)
14. Marco F, Pfaller MA, Messer SA, Jones RN. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 1998;36:433-436.
15. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
16. Diemert D, Kunimoto D, Sand C, Rennie R. Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis. Scand J Infect Dis 2001;33:777-779. (Pubitemid 33041124)
17. Pihet M, Carrere J, Cimon B, Chabasse D, Delhaes L, Symoens F, Bouchara JP. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis - A review. Med Mycol 2009;47:387-397.
18. Nagano Y, Millar BC, Johnson E, Goldsmith CE, Elborn JS, Rendall J, Moore JE. Fungal infections in patients with cystic fibrosis. Rev Med Microbiol 2007;18:11-16. (Pubitemid 47266699)
19. Nagano Y, Millar BC, Goldsmith CE, Elborn JS, Rendall J, Moore JE. Emergence of Scedosporium apiospermum in patients with cystic fibrosis. Arch Dis Child 2007;92:607.
20. Kusenbach G, Skopnik H, Haase G, Friedrichs F, Dohmen H. Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr 1992;151:344-346.
21. de Hoog GS, Takeo K, Yoshida S, Gottlich E, Nishimura K, Miyaji M. Pleoanamorphic life cycle of Exophiala (Wangiella) dermatitidis. Antonie Van Leeuwenhoek 1994;65:143-153. (Pubitemid 24247704)
22. Matsumoto T, Matsuda T, McGinnis MR, Ajello L. Clinical and mycological spectra of Wangiella dermatitidis infections. Mycoses 1993;36:145-155. (Pubitemid 23294842)
23. Szaniszlo PJ. Molecular genetic studies of the model dematiaceous pathogen Wangiella dermatitidis. Int J Med Microbiol 2002;292:381-390.